Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$2.18 -0.9%	$2.20	$0.98 ▼ $3.44	$87.89M	0.17	31,866 shs	12,767 shs
CLYM Climb Bio	$1.51 +3.4%	$1.27	$1.05 ▼ $9.21	$102.04M	-0.13	384,359 shs	159,187 shs
CYTH Cyclo Therapeutics	$0.72	$0.72	$0.55 ▼ $1.45	$23.72M	-0.57	580,491 shs	N/A
WHWK Whitehawk Therapeutics	$1.80 -2.7%	$0.00	$1.21 ▼ $3.81	$84.80M	0.55	163,230 shs	75,829 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	0.00%	-5.63%	-29.90%	+66.41%	-5.05%
CLYM Climb Bio	0.00%	+10.22%	+22.76%	+19.84%	+150,999,900.00%
CYTH Cyclo Therapeutics	0.00%	0.00%	0.00%	0.00%	-42.81%
WHWK Whitehawk Therapeutics	0.00%	-5.76%	+179,999,900.00%	+179,999,900.00%	+179,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	2.6128 of 5 stars	3.6	0.0	0.0	0.0	0.6	2.5	1.3
CYTH Cyclo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BYSI BeyondSpring	0.00	N/A	N/A	N/A
CLYM Climb Bio	3.25	Buy	$9.00	496.03% Upside
CYTH Cyclo Therapeutics	2.33	Hold	$0.95	31.83% Upside
WHWK Whitehawk Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CYTH, WHWK, CLYM, and BYSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$7.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BYSI BeyondSpring	$1.75M	50.23	N/A	N/A	($0.37) per share	-5.89
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.15 per share	N/A
CYTH Cyclo Therapeutics	$870.73K	27.24	N/A	N/A	$0.21 per share	3.43
WHWK Whitehawk Therapeutics	$25.98M	3.26	N/A	N/A	$2.12 per share	0.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	-$73.90M	-$2.38	N/A	N/A	N/A	N/A	-43.95%	-42.94%	8/13/2025 (Estimated)
CYTH Cyclo Therapeutics	-$20.06M	-$0.90	N/A	N/A	N/A	-2,847.19%	N/A	-307.16%	N/A
WHWK Whitehawk Therapeutics	-$63.69M	$0.16	11.25	∞	N/A	99.42%	-56.73%	-48.68%	N/A

Latest CYTH, WHWK, CLYM, and BYSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	CLYM Climb Bio	-$0.19	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	CLYM Climb Bio	-$0.15	-$0.31	-$0.16	-$0.31	N/A	N/A
5/12/2025	Q1 2025	BYSI BeyondSpring	N/A	-$0.06	N/A	$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
CYTH Cyclo Therapeutics	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BYSI BeyondSpring	N/A	2.49	2.49
CLYM Climb Bio	N/A	14.25	14.25
CYTH Cyclo Therapeutics	N/A	0.17	0.16
WHWK Whitehawk Therapeutics	N/A	18.95	18.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BYSI BeyondSpring	40.29%
CLYM Climb Bio	69.76%
CYTH Cyclo Therapeutics	68.55%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
BYSI BeyondSpring	29.31%
CLYM Climb Bio	0.80%
CYTH Cyclo Therapeutics	29.78%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BYSI BeyondSpring	80	40.32 million	28.50 million	Optionable
CLYM Climb Bio	9	67.58 million	67.04 million	N/A
CYTH Cyclo Therapeutics	9	32.92 million	23.12 million	No Data
WHWK Whitehawk Therapeutics	40	47.11 million	23.60 million	N/A

CYTH, WHWK, CLYM, and BYSI Headlines

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTH, WHWK, CLYM, and BYSI Company Descriptions

BeyondSpring NASDAQ:BYSI

$2.18 -0.02 (-0.91%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.18 +0.00 (+0.23%)

As of 07/18/2025 04:23 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Climb Bio NASDAQ:CLYM

$1.51 +0.05 (+3.42%)

As of 07/18/2025 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Cyclo Therapeutics NASDAQ:CYTH

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Whitehawk Therapeutics NASDAQ:WHWK

$1.80 -0.05 (-2.70%)

As of 07/18/2025 04:00 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time